The adaptive immune response is initiated in secondary lymphoid organs (SLOs), including lymph nodes (LNs), spleen and Peyer's patches (PPs) in the intestine. These organs act as elaborate filters, located in strategic sites to maximize the chance of an encounter between lymphocytes and antigens. Despite their different macroscopic structure, they all share a complex microanatomy and the common feature of lymphocyte segregation in two different compartments, the T-and B-cell area. The T-cell area is densely populated by CD4 + and CD8 + T cells, as well as dendritic cells (DCs), while the B-cell area contains B-cells aggregated in follicles 1 . Behind this compartmentalization lies a heterogeneous population of non-hematopoietic cells that produce a variety of chemokines to attract leucocytes to each area [2] [3] [4] . Two major such cell populations are the most prominent: endothelial cells that are involved in the trafficking between the blood and the lymph, and stromal cells, which are responsible for the microdomain formation and maintenance of SLOs 5, 6 . During embryonic development, stromal cells in SLOs originate from mesenchymal precursors 7, 8 which interact with hematopoietic lineage cells to induce a differentiation program 9 . First, mesenchymal precursors are differentiated into lymphoid tissue organizer cells (LTo cells) through interactions with lymphoid tissue inducer cells (LTi cells). Later, B and T cells induce the differentiation of LTo cells in at least three subpopulations: fibroblastic reticular cells (FRCs) in the T-cell area, follicular dendritic cells (FDCs) in the B-cell area and marginal reticular cells (MRCs) in the SLO periphery 2, 10 . FRCs play a crucial role in T cell maintenance through the production of survival factors, such as IL-7 11 , in the guidance of T cell and DC migration through CCL19 and CCL21 secretion 3 and in the formation of a microvascular conduit system that distributes small antigens within SLOs 12 . Similarly, FDCs are important for the B-cell area maintenance through the production of B cell survival factors, such as IL-15 or BAFF 13, 14 , the guidance of B cell migration through CXCL12 and CXCL13 15, 16 and the facilitation of high-affinity antibody production in germinal centers 17 . Finally, MRCs are the most recent stromal cell population described 18 and they are still poorly characterized. Jarjour et al., however, recently showed that MRCs can function as FDC precursors in LNs 19 . Besides FRCs, FDCs and MRCs, which are the major stromal populations in adult SLOs, additional stromal cell types are also present in virtually all these tissues. These include cells surrounding blood and lymphatic vessels, generally called pericytes, which have important functions in vascular morphogenesis, hemostasis, and lymph propulsion 20, 21 . The precise origin of these cells, as well as the relationship between them and other stromal cell types in SLOs is not clearly defined.
The elucidation of the origin, properties and functions of individual cell populations is facilitated by the use of appropriate genetic tools for their specific manipulation. The development of the Cre-LoxP system has provided such a powerful tool in combination with genetic targeting and cell lineage tracing approaches. This technology is based on the expression of the bacteriophage P1 Cre-recombinase under the control of cell type-specific promoters 22 . In the case of SLOs, the most common genetic tools used for the study of SLO stromal cells include the CD21-Cre mice that target FDCs in all SLOs, the PDPN-Cre mice that target FRCs in LNs and CCL19-Cre mice that target FRCs in all SLOs [23] [24] [25] [26] . These strains, however, show also some specificity for other non-stromal populations, such as B cells 23 , endothelial cells 24 or epithelial cells 27 , while there is no genetic tool to target MRCs to date. In this study, we used a transgenic mouse strain that expresses Cre-recombinasese under the CollagenVI promoter (ColVI-Cre mice) in combination with cell lineage approaches. We show that ColVI-Cre mice specifically target MRCs and FDCs, but not FRCs in PPs. We also demonstrate that FDCs and MRCs in other SLOs are not targeted, with the exception of a small fraction in peripheral lymph nodes (pLNs). Finally, we show that ColVI-Cre mice target pericytes around blood, but not lymphatic, vessels in all SLOs tested. ColVI-cre mice could therefore, facilitate the analysis of MRC-and FDC-specific functions and plasticity in the gut-associated lymphoid tissue (GALT).
Results

ColVI-Cre mice target FDCs and MRCs in PPs.
We have previously demonstrated that ColVI-Cre transgenic mice show specificity for mesenchymal cells in the intestine, synovium and skin 28, 29 . Since FDCs and FRCs can originate from myofibroblastic precursors 7, 25 we analyzed the specificity of this mouse strain for stromal populations in different SLOs. To accomplish this, we crossed ColVI-Cre mice to Rosa26 mT/mG reporter mice 30 . These mice normally express the membrane-targeted Tomato protein (mT), which is excised after Cre-mediated recombination, allowing thus for the expression of the membrane-targeted green fluorescent protein (mG).
Confocal laser-scanning microscopy of PPs from ColVI-Cre × Rosa26 mT/mG revealed expression of the ColVI-Cre transgene mainly in stromal cells within the B-cell area and only in a few cells of the T-cell area (Fig. 1A) . To better characterize the pattern of the transgene expression, PP sections were further stained with a combination of markers, so as to identify FDC, MRC, and FRC-specific networks. GFP positive MRCs were identified as TRANCE + and MAdCAM-1 + cells located under the epithelial dome (Fig. 1B) . FDCs, detected near the muscularis layer as CD35 + and CXCL13 + cells, also exhibited high GFP expression (Fig. 1C) . In contrast, FRCs, identified as cells expressing ERTR7 and CCL21 in the T cell area, were GFP negative (Fig. 1D) .
To quantify the transgene expression in PPs, we next performed FACS analysis. Flow cytometry showed that GFP expression was specific for the stromal compartment, since hematopoietic (CD45 + ) and endothelial cells (CD45 − CD31 + ) were not targeted by ColVI-Cre mice ( Fig. 2A) , in agreement to what has been previously published 28, 29 . To discriminate between PP stromal cells and intestinal mesenchymal cells, which are also ColVI-Cre . These results suggest that ColVI-Cre mice can be a unique tool for the specific targeting of FDCs and MRCs, but not FRCs, in PPs without any specificity for non-stromal cell types. Moreover, their potential specificity for other under-represented stromal populations in the B-cell area could prove important for their further characterization.
ColVI-Cre mice target stromal cells in isolated lymphoid follicles in the intestine. PPs are part of the GALT along with isolated lymphoid follicles (ILFs). ILFs were described relatively recently as single B-cell aggregates with an architecture and cellular composition similar to PPs 32, 33 . They develop postnatally and their size and composition depends on external stimuli and commensal bacteria, producing a spectrum of appearances ranging from small B cell clusters (immature ILFs) to well-organized lymphoid structures containing germinal centers (mature ILFs) 34 . Apart from B and T-cells they also include stromal cells, which are still poorly characterized. Using ColVI-Cre-Rosa26 mT/mG mice, we further identified GFP expression inside both immature and mature ILFs, which co-localized with MAdCAM-1 and CD35 expression, marking MRCs and FDCs, respectively (Fig. 3) . We also observed a continuous GFP + network that connects the intestinal and ILF stroma, suggesting a close relationship between the two cell populations. Together, these results indicate that ColVI-Cre mice may be used to target particular stromal subsets in the GALT and could help to elucidate both their specific functions and their potential ontogenetic relationships.
ColVI-Cre mice do not show specificity for stromal cells in mesenteric LNs or the spleen. Applying similar immunofluorescent techniques, we also analyzed pLNs and more specifically, inguinal and axillar LNs, as well as mesenteric LNs (mLNs). In contrast to PPs, we could mainly detect transgene activity in the collagen capsule, but not in stromal cells in either the T-cell or B-cell area, as shown both by confocal microscopy ( Fig. 4A ) and FACS analysis (Fig. 4B) . GFP + cells were especially rare in mLNs ( and MRCs were GFP positive (Fig. 4A,B) . In both cases, we could not detect GFP expression in the FRC network, marked as podoplanin positive cells. Accordingly, similar analysis of the spleen showed that GFP + cells were equally rare and only a few cells could be detected in the central area of the white pulp (Fig. 4C) . Again, co-staining with stromal specific markers and analysis by confocal microscopy showed lack of GFP expression by FDCs, MRCs or FRCs. These results suggest that, in contrast to PPs, other SLOs, including pLNs, mLNs and the spleen, are not targeted by the ColVI-Cre mouse strain (Table 1) , which may allow for the analysis of local SLO stromal cell functions in the intestine, Pericytes are targeted by ColVI-Cre in all SLOs. During the previous experiments, we noticed that GFP + cells could also be found around vessels in all SLOs analyzed. To identify whether ColVI-Cre + cells were found around both blood and lymphatic vessels, we stained tissues with CD31, a common marker for blood (BECs) and lymphatic endothelial cells (LECs), and LYVE-1, which is specific only for LECs. In PPs and LNs, GFP + cells were found surrounding CD31-positive endothelial cells in both T and B cell areas, but not LYVE-1 + LECs (Fig. 5A,B) . In the spleen, high-resolution analysis revealed that GFP + cells were mainly located surrounding CD31
+ cells in the central arteriole (Fig. 5C) . These data indicate different properties and origin for blood and lymphatic pericytes in SLOs, and ColVI-Cre mice could be a useful new tool to discern the specific role of pericytes in cell trafficking regulation between blood and SLOs.
Discussion
In this study, we analyzed the cell-specificity of the ColVI-Cre transgenic mouse strain in SLOs, including the spleen, pLNs, mLNs and PPs in the intestine, in addition to the known specificities for mesenchymal cells in the intestine, synovium and skin 28, 29 . We show that ColVI-Cre mice do not show any specificity for hematopoietic, epithelial or endothelial cell lineages and that cre recombinase specificity is confined to the GALT stroma. We further show that ColVI-Cre marks FDCs and MRCs in PPs, as well as stromal cells in ILFs, while they show no specificity for FRCs and stromal cells in other SLOs. Furthermore, it is the first strain that to our knowledge specifically targets MRCs in vivo, offering, thus new possibilities for the functional characterization of this cell population during development and in immunity. It should be noted that the additional specificities of the ColVI-cre mouse, especially for other mesenchymal cells in the intestine, might complicate targeting strategies when used with floxed mice and caution is needed in the interpretation of results. However, we believe that it is still a valuable tool for the study of specific stromal cell function in the GALT, independently of relevant stromal cell function in other SLOs and particularly closely related mLNs. PPs, LNs and the white pulp of the spleen bear developmental, cellular and molecular similarities. According to the current SLO developmental model, FDCs, MRCs and FRCs originate from a common mesenchymal precursor [7] [8] [9] ; however, it is likely to be a different one depending on the organ. In fact, an organ-specific stromal precursor has been identified in the spleen, and it does not play a role in the development of the LN and PP stroma 8 . Our results further support this hypothesis, since we have detected ColVI-Cre expression only in stromal networks in PPs and ILFs, but not in mLNs or the spleen. The presence of a few GFP + cells in pLNs may also point to the existence of several stromal precursors in LNs and it is now well-established that pLNs and mLNs have different developmental requirements 9 and differences in their respective stromal precursor have been reported 35 . Mesenchymal precursor differentiation into mature stromal cells happens in several steps. First, precursors are differentiated into LTo cells, defined by high ICAM-1 and VCAM-1 expression and by the upregulation of essential molecules involved in organogenesis, including CCL19, CXCL13 or TRANCE 36, 37 . Later, when lymphocytes arrive into the SLO primordium, LTo cells are differentiated into FRCs, FDCs or MRCs, depending on the lymphoid region 38, 39 . The connection between these populations and LTo cells is still controversial, with some reports suggesting a close developmental relationship between FRCs and MRCs 40 , while others have shown a different developmental pathway using the CCL19-Cre mice 25 . Our work is in agreement with Chai et al., and further supports the hypothesis that there are different precursors for FRCs and MRCs at least in PPs, since ColVI-Cre mice target MRCs, but not FRCs. The relation between MRCs and FDCs seems to be more clear, since a recent paper has corroborated that MRCs can act as a source of FDCs in LNs 19 . Similarly, in the ColVI-Cre mice, both cell types showed reporter gene expression, which indicates an ontogenic relationship between the two cells types in PPs, although we cannot exclude that adult PP MRCs and FDCs use Collagen VI gene and, as consequence, both of them express GFP, under the control of the ColVI promoter. It is also obvious from our studies that ColVI-Cre mice do not target the 100% of either MRCs or FDCs. This indicates that ColVI-Cre + cells are not early progenitors and that they probably appear in later developmental stages or that more than one cell types can act as PP stromal cell progenitor cells, which needs to be further analyzed through experiments in the PP anlangen. Besides FDCs and MRCs in the B cell area, other subpopulations have also been described, such as CRCs or FSCs 15, 31 . However, these cell types are poorly characterized mainly due to the lack of specific cell surface markers. Interestingly, the ColVI-Cre mouse line displayed a transgene expression pattern that could indicate its expression in these stromal cell subpopulations, since we have noted the presence of GFP + CD35 − MAdCAM-1 − cells near to the muscular layer and between FDC and MRC networks, where CRCs and FSCs are respectively located and it could therefore facilitate their characterization. GFP + CD35 − MAdCAM-1 − cells were also identified by FACS. A relationship between these rare stromal cell populations and FRCs has previously been suggested due to phenotypic similarities and their common targeting by CCL19-Cre mice in LNs and PPs 31, 41 . However, our data suggest that at least in PPs, there is a common origin only for stromal cells in the B cell area and not FRCs. Future experiments using multi-fluorescent reporter mice are required to further clarify the cell ontogeny in the different SLOs.
It has also been recently demonstrated that spleen FDCs originate from a perivascular precursor 7 . This location is occupied by different stromal cell types, such as vascular smooth muscle cells (vSMCs), fibroblasts or pericytes. However, there is no single molecular marker known to distinguish them 20 . Here, we demonstrated that ColVI-Cre mice also target perivascular cells in all SLOs, including the spleen. Nevertheless, this population should be different from the FDC precursor, described by Krautler et al., since we could not identify GFP expression in spleen FDCs. Similar results have been also shown by Onder et al., who have identified a perivascular cell type targeted by PDPN-Cre mice, which does not act as a precursor of FDCs in the spleen 24 . Taking into consideration that these cells are not involved in the formation of the stroma, they could have a role in the maintenance of endothelial venule integrity 42 . The finding that ColVI-Cre mice also label stromal cells in ILFs offers a first indication that tertiary lymphoid structures (TLOs) could also be targeted in this mouse strain. In contrast to the spleen, LNs and PPs, ILFs are inducible structures developed after birth due to the presence of external stimuli 43 . They are widely associated with infection and chronic inflammation, however, their role in these pathologies is still controversial, as they can either contribute to the local protective immune response or support disease progression 44 . It would, therefore be interesting to further examine tertiary lymphoid organogenesis in this mouse strain, both in the intestine and the peripheral SLOs and discern the ontogenic and functional relationships between pericytes, mesenchymal stromal and lymphoid stromal cells under such conditions. In summary, the ColVI-Cre mouse model is a promising new tool to target stromal cells in the B cell area and the first one that targets MRCs in the GALT. We believe that this transgenic line could be a valuable tool for the manipulation of gene expression in the follicular stroma without affecting stromal cell lineages in other SLOs and for the clarification of the relationship between them and the rest of SLO stromal cells. Ultimately, this could assist in the elucidation of stromal-immune interaction both in homeostasis and in disease.
Materials and Methods
Mice. The generation of ColVI-Cre mice has been previously described 28 . ColVI-Cre mice were crossed with R26 mT/mG reporter mice 30 to analyze Cre-recombinase expression. All mice were bred and maintained on a C57BL/6J genetic background in the animal facilities of the Biomedical Sciences Research Center "Alexander Fleming" under specific pathogen-free conditions. Experiments were approved by the Institutional Committee of Protocol Evaluation in conjunction with the Veterinary Service Management of the Hellenic Republic Prefecture of Attika according to all current European and national legislation and were performed in accordance with relevant guidelines and regulations.
Immunohistochemistry. LNs, spleens and small intestines containing PPs were harvested, washed with PBS, fixed in 4% PFA for 1 hour and snap-frozen in an OCT-filled mold on a liquid nitrogen-cooled metal surface. Cryosections 10 μ m were rehydrated in wash buffer (0.1% saponin in PBS) for 5 min and blocked in PBS containing 0.5% albumin for 30 min. Sections were incubated with antibodies against: collagen IV and ER-TR7 from Abcam; TRANCE, eFluor 660-conjugated anti-podoplanin and anti-Lyve1 from eBioscience; CXCL13 and CCL21 from R&D Systems; CD31 and CD35 from BD Pharmigen; MAdCAM-1, Alexa Fluor 594-conjugated anti-CD3 and Alexa Fluor 647-conjugated anti-B220 from Biolegend; and Alexa Fluor 488-conjugated anti-GFP from Invitrogen. Unconjugated antibodies were detected with the following secondary antibodies: Alexa Fluor 594-conjugated anti-rat-IgG, Alexa Fluor 568-conjugated anti-rabbit-IgG all purchased from Invitrogen. TRANCE, CXCL13 and CCL21 expression were detected using the tiramide amplification signal kit (Applied biosystem). Finally, images were acquired with a TCS SP8X White Light Laser confocal system (Leica). Collagenese P (Roche) and 0.1 mg/ml DNase I (Sigma) for 50 min at 37 °C, as it was described previously 45 . To further enrich the stromal cell fraction, lymphocytes were depleted by incubating the cell suspension with MACS anti-CD45 microbeads and passing over a MACS LS column (Miltenyi Biotec). The cells in the flow-through were collected and analyzed by flow cytometry. Viability, assessed by trypan blue exceeded 90%.
Stromal cell isolation. PPs and
Flow cytometry analysis. Stromal cells were suspended in FACS buffer (PBS supplemented with 0.5% bovine serum albumin (BSA) and 5 mM EDTA in PBS) at 10 7 cells/ml and blocked using 4% of normal mouse serum. 100 μ l of cell suspension was stained for 30 min at 4 °C using the following antibodies: PerCP-conjugated anti-CD31 (clone 390), PE-Cy7-conjugated anti-VCAM-1, PE-Cy7-conjugated anti-podoplanin, Alexa Fluor 700 conjugated anti-CD45, APC-Cy7-conjugated anti-CD21/CD35 and anti-MAdCAM-1 (Biolegend). Alexa Fluor 647-conjugated anti-rat-IgG (Invitrogen) was used as a secondary antibody to detect MAdCAM-1 expression. Finally, cells were acquired on a FACSCANTO II (BD Bioscience) and data were analyzed using Flowjo software (Tree star Inc). 
